AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8725733 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiplatelet medication)
Number of subjects: 115
Study 1533312 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed intra-nasal mupirocin ointment
Number of subjects: 30
Study 1533312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3890132 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine, 2 g i.v. three times per week
Number of subjects: 28
Study 3890132 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 28
Study 29369674 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) comparing their drinking and perceived norms to actual drinking rates for same sex veterans
Number of subjects: 784
Study 29369674 — intervention group
Group type: COMPARATOR
Intervention: Feedback about same sex veteran video game play (control condition)
Number of subjects: 784
Study 29328027 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy (recombinant growth hormone injection once weekly for 12 months)
Number of subjects: 20
Study 29328027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26651472 — intervention group
Group type: EXPERIMENTAL
Intervention: TEXT intervention (bidirectional text messaging)
Number of subjects: 63
Study 26651472 — intervention group
Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 63
Study 23207959 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidafenacin (0.1 mg twice daily)
Number of subjects: 109
Study 23207959 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin (5 mg once daily)
Number of subjects: 109
Study 22041946 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin therapy
Number of subjects: 10041
Study 22041946 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (aspirin alone)
Number of subjects: 10041
Study 17625501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg orally twice daily
Number of subjects: 212
Study 17625501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 17135729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GLP-1 (0.9 pmol/kg/min)
Number of subjects: 12
Study 17135729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GLP-1 (0.9 pmol/kg/min) with a protein preload (400 ml protein shake)
Number of subjects: 12
Study 17135729 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 17135729 — intervention group
Group type: EXPERIMENTAL
Intervention: Preload of 400 ml water or 400 ml protein shake
Number of subjects: 12
Study 14749629 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal sacral colpopexy
Number of subjects: 95
Study 14749629 — intervention group
Group type: COMPARATOR
Intervention: Vaginal sacrospinous colpopexy
Number of subjects: 95
Study 11152378 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz (oral administration for 2 weeks)
Number of subjects: 11
Study 9461727 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergovit immunotherapy
Number of subjects: 0
Study 9461727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no desensitization)
Number of subjects: 0
Study 7530963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic drugs
Number of subjects: 104
Study 3395666 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A
Number of subjects: 12
Study 3395666 — intervention group
Group type: COMPARATOR
Intervention: Formulation B
Number of subjects: 12
Study 3395666 — intervention group
Group type: COMPARATOR
Intervention: Formulation C
Number of subjects: 12
Study 30281041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 0
Study 27741006 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (ELC)
Number of subjects: 86
Study 27741006 — intervention group
Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy (DLC)
Number of subjects: 86
Study 23980910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprescriptive dietary intervention based on UK dietary guidelines
Number of subjects: 262
Study 22222193 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐IUS12
Number of subjects: 738
Study 22222193 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐IUS16
Number of subjects: 738
Study 22222193 — intervention group
Group type: COMPARATOR
Intervention: Mirena
Number of subjects: 738
Study 20696154 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg GMZ2 vaccine
Number of subjects: 40
Study 20696154 — intervention group
Group type: COMPARATOR
Intervention: Rabies control vaccine
Number of subjects: 40
Study 18240099 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinaforce tablets
Number of subjects: 3
Study 18240099 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinaforce Junior tablets
Number of subjects: 3
Study 18240099 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea sore throat spray
Number of subjects: 3
Study 16548353 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw rhubarb (RR) 9 g/d
Number of subjects: 40
Study 16548353 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 40
Study 12834313 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin at doses of 50 mg/kg, 250 mg/kg, or 500 mg/kg weekly from day ‐7 to day 100 after transplantation
Number of subjects: 200
Study 12834313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12834313 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin
Number of subjects: 200
Study 11728260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 18895
Study 11728260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril with ASA
Number of subjects: 18895
Study 11728260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril without ASA
Number of subjects: 18895
Study 11728260 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA and Lisinopril
Number of subjects: 18895
Study 8784653 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 36
Study 8784653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1531677 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol and ipratropium bromide
Number of subjects: 0
Study 1531677 — intervention group
Group type: COMPARATOR
Intervention: Albuterol alone
Number of subjects: 0
Study 1531677 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide alone
Number of subjects: 0
Study 6374684 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxyphylline (2400 mg/day)
Number of subjects: 10
Study 6374684 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (800 mg/day)
Number of subjects: 10
Study 6374684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31278225 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus of IV ondansetron at a dose of 0.2 mg/kg
Number of subjects: 61
Study 31278225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 29490302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by exemestane (tamoxifen‐exemestane group)
Number of subjects: 108
Study 29490302 — intervention group
Group type: COMPARATOR
Intervention: Exemestane (exemestane‐only group)
Number of subjects: 108
Study 29490302 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 27291501 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone solution 2% (TS)
Number of subjects: 694
Study 27291501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 694
Study 25223208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular draping
Number of subjects: 262
Study 25223208 — intervention group
Group type: COMPARATOR
Intervention: No ocular draping
Number of subjects: 262
Study 22849413 — intervention group
Group type: EXPERIMENTAL
Intervention: Accused of cheating (n = 15)
Number of subjects: 30
Study 22849413 — intervention group
Group type: COMPARATOR
Intervention: Not accused of cheating (n = 15)
Number of subjects: 30
Study 20522464 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg for 5-12 years, 10 mg for >12 years)
Number of subjects: 117
Study 20522464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 20522464 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and Placebo (both groups)
Number of subjects: 117
Study 18525261 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous antiretroviral therapy
Number of subjects: 36
Study 18525261 — intervention group
Group type: COMPARATOR
Intervention: 6-week antiretroviral therapy interruption
Number of subjects: 36
Study 18525261 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy interruption extended to viral set point
Number of subjects: 36
Study 18525261 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of antiretroviral therapy
Number of subjects: 36
Study 15996071 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg IL-1Ra
Number of subjects: 14
Study 12499348 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based feeding intervention with meat
Number of subjects: 200
Study 12499348 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based feeding intervention with milk
Number of subjects: 200
Study 12499348 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based feeding intervention with nonanimal-source foods
Number of subjects: 200
Study 12499348 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 200
Study 10230262 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA serum
Number of subjects: 130
Study 10230262 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA saliva
Number of subjects: 130
Study 10230262 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 130
Study 9569804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy with local metronidazole administration
Number of subjects: 10
Study 9569804 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical periodontal therapy without local metronidazole administration
Number of subjects: 10
Study 1871705 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 or 400 micrograms)
Number of subjects: 23
Study 1871705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3877292 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 3877292 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 20
Study 31389049 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus species RV-A
Number of subjects: 547
Study 31389049 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus species RV-B
Number of subjects: 547
Study 31389049 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus species RV-C
Number of subjects: 547
Study 31389049 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall rhinovirus types
Number of subjects: 547
Study 31389049 — intervention group
Group type: COMPARATOR
Intervention: Reported respiratory symptoms
Number of subjects: 547
Study 31389049 — intervention group
Group type: EXPERIMENTAL
Intervention: Median ages at illness onset
Number of subjects: 547
Study 31389049 — intervention group
Group type: EXPERIMENTAL
Intervention: Median PCR cycle threshold values
Number of subjects: 547
Study 31389049 — intervention group
Group type: COMPARATOR
Intervention: Association between RV species and disease severity
Number of subjects: 547
Study 29196963 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 40 mg/day
Number of subjects: 54
Study 29196963 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (LET) 2.5 mg/day
Number of subjects: 54
Study 26948184 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg mifepristone followed by 400-mcg misoprostol vaginally 4-6h prior to D&E
Number of subjects: 100
Study 26948184 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo followed by 400-mcg misoprostol vaginally 4-6h prior to D&E
Number of subjects: 100
Study 25304996 — intervention group
Group type: EXPERIMENTAL
Intervention: Public Reporting (PR) intervention group
Number of subjects: 34815
Study 25304996 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34815
Study 21749167 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Treatment Group (ETG): plaque control and root planing plus amoxicillin and metronidazole
Number of subjects: 165
Study 21749167 — intervention group
Group type: COMPARATOR
Intervention: Control Treatment Group (CTG): plaque control instructions, supragingival scaling, and two placebos
Number of subjects: 165
Study 21749167 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165
Study 21749167 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Treatment Group (ETG)
Number of subjects: 165
Study 20729710 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream applied three times a week for 4 months
Number of subjects: 64
Study 20729710 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied three times a week for 4 months
Number of subjects: 64
Study 20729710 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label imiquimod treatment for a further 4 months after initial treatment
Number of subjects: 64
Study 20729710 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall follow-up after treatment
Number of subjects: 64
Study 22300431 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive belatacept regimen (MI)
Number of subjects: 543
Study 22300431 — intervention group
Group type: EXPERIMENTAL
Intervention: Less intensive belatacept regimen (LI)
Number of subjects: 543
Study 22300431 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 543
Study 15749145 — intervention group
Group type: EXPERIMENTAL
Intervention: AF1996 cohort (N = 29,036)
Number of subjects: 60116
Study 15749145 — intervention group
Group type: EXPERIMENTAL
Intervention: AF2000 cohort (N = 31,080)
Number of subjects: 60116
Study 15749145 — intervention group
Group type: EXPERIMENTAL
Intervention: Male recruits ages 25‐29 in AF1996
Number of subjects: 60116
Study 15749145 — intervention group
Group type: EXPERIMENTAL
Intervention: Male recruits ages 25‐29 in AF2000
Number of subjects: 60116
Study 15749145 — intervention group
Group type: COMPARATOR
Intervention: AF1996 cohort compared to BRFSS 1996
Number of subjects: 60116
Study 15749145 — intervention group
Group type: COMPARATOR
Intervention: AF2000 cohort compared to BRFSS 2000
Number of subjects: 60116
Study 12377682 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialists
Number of subjects: 288
Study 12377682 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalists
Number of subjects: 288
Study 9814491 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (10(-6) mol/L)
Number of subjects: 48
Study 9814491 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise
Number of subjects: 48
Study 9814491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 48
Study 9814491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol dilution for local blood flow
Number of subjects: 48
Study 8123955 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact intervention (weekly calls from a healthcare professional during the first month of drug therapy)
Number of subjects: 81
Study 8123955 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 81
Study 2510286 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil + Aspirin
Number of subjects: 166
Study 2510286 — intervention group
Group type: COMPARATOR
Intervention: Aspirin + Placebo
Number of subjects: 166
Study 5135250 — intervention group
Group type: EXPERIMENTAL
Intervention: mefruside
Number of subjects: 45
Study 5135250 — intervention group
Group type: COMPARATOR
Intervention: frusemide
Number of subjects: 45
Study 31558040 — intervention group
Group type: EXPERIMENTAL
Intervention: SBS app (experimental group)
Number of subjects: 265
Study 31558040 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 265
Study 30118448 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT-derived intervention
Number of subjects: 45
Study 30118448 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 45
Study 28836809 — intervention group
Group type: COMPARATOR
Intervention: TOPS-F
Number of subjects: 152
Study 28836809 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPS-TO
Number of subjects: 152
Study 28836809 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPS-F and TOPS-TO
Number of subjects: 152
Study 25467738 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified quadrangular Le Fort I osteotomy (MQLI)
Number of subjects: 40
Study 25467738 — intervention group
Group type: COMPARATOR
Intervention: Conventional Le Fort I osteotomy (LFI)
Number of subjects: 40
Study 25467738 — intervention group
Group type: COMPARATOR
Intervention: Both MQLI and LFI
Number of subjects: 40
Study 23561230 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive psychotherapy for depression (n = 62)
Number of subjects: 106
Study 23561230 — intervention group
Group type: COMPARATOR
Intervention: collaborative care (n = 44)
Number of subjects: 106
Study 21379571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascent profiles during the expedition to high altitudes (up to 6865 m)
Number of subjects: 28
Study 21379571 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation (SpO₂) and hematocrit assessments
Number of subjects: 28
Study 19004198 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Jiaji L4‐S1, Waiqiu (GB 36), Weizhong (BL 40), Xiaxi (GB 43) plus intervention injection of Gegensu Zhusheye (Puerarin Injectio)
Number of subjects: 60
Study 19004198 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture combined with injection of Gegensu Zhusheye (Puerarin Injectio) into Ashi points
Number of subjects: 60
Study 19004198 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16600840 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention and referral to a nutritionist (from the beginning of olanzapine treatment in 9 patients)
Number of subjects: 18
Study 16600840 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention and referral to a nutritionist (from the 9th week of therapy in 8 patients)
Number of subjects: 18
Study 16600840 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational approach from the beginning
Number of subjects: 18
Study 16600840 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean dosages of olanzapine
Number of subjects: 18
Study 16600840 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor dietary compliance
Number of subjects: 18
Study 12635791 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation using 2 von Bahr screws (n = 53)
Number of subjects: 100
Study 12635791 — intervention group
Group type: COMPARATOR
Intervention: Bipolar Variokopf prosthesis (n = 47)
Number of subjects: 100
Study 10908256 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 58
Study 10908256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 8970048 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg betamethasone + 4 cm3 of 1% lidocaine
Number of subjects: 75
Study 8970048 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg betamethasone + 4 cm3 of 1% lidocaine
Number of subjects: 75
Study 8970048 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg betamethasone + 4 cm3 of 1% lidocaine
Number of subjects: 75
Study 1420996 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra (1 mg/kg)
Number of subjects: 25
Study 1420996 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra (10 mg/kg)
Number of subjects: 25
Study 1420996 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra (1 mg/kg and 10 mg/kg)
Number of subjects: 25
Study 1420996 — intervention group
Group type: COMPARATOR
Intervention: IL-1ra
Number of subjects: 25
Study 4047702 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (60 mg)
Number of subjects: 6
Study 4047702 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1 g)
Number of subjects: 6
Study 4047702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30575804 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 0
Study 30575804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29921561 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intervention
Number of subjects: 212
Study 29921561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intervention
Number of subjects: 212
Study 29921561 — intervention group
Group type: COMPARATOR
Intervention: Control (stress and sleep contact)
Number of subjects: 212
Study 27785375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine 10 mg tablets
Number of subjects: 28
Study 27785375 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 28
Study 25092936 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone peer counseling (4 or 8 contacts)
Number of subjects: 1948
Study 25092936 — intervention group
Group type: COMPARATOR
Intervention: No peer counseling
Number of subjects: 1948
Study 22691101 — intervention group
Group type: EXPERIMENTAL
Intervention: Agrippal® (trivalent vaccine)
Number of subjects: 1893
Study 22691101 — intervention group
Group type: COMPARATOR
Intervention: Fluvirin® (control trivalent vaccine)
Number of subjects: 1893
Study 20130863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic levothyroxine (LT4) treatment (75‐125 microg/day)
Number of subjects: 150
Study 20130863 — intervention group
Group type: COMPARATOR
Intervention: No postoperative LT4 treatment
Number of subjects: 150
Study 20130863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic levothyroxine (LT4) treatment (75‐125 microg/day) among iodine-deficient patients
Number of subjects: 150
Study 20130863 — intervention group
Group type: COMPARATOR
Intervention: No postoperative LT4 treatment among iodine-deficient patients
Number of subjects: 150